Glaucoma Newswire

Comprehensive Real-Time News Feed for Glaucoma.

Results 1 - 20 of 297 in Glaucoma

  1. If Big Pharma Isn't Nervous, It Should BeRead the original story

    4 hrs ago | BayStreet.ca

    ... efficacy, albeit somewhat anecdotal, in the treatment of a host of afflictions ranging from cancer to epilepsy, glaucoma, MS, Tourette's and even eczema. To date there have been approximately 100 cannabinoids identified; each with the potential to ...

    Comment?

  2. Yvonne Nelson Says She's Single Because Men Are Not LoyalRead the original story w/Photo

    Yesterday | Ghanamma.com

    ... She said that if anyone has a problem with her, then it's his/her own issue. According to the bubbly actress, her glaucoma foundation is a little bit shaky now because there is not enough funding to cater for the victims. She said most of the drugs ...

    Comment?

  3. iStent provides permanent relief for glaucoma patientsRead the original story w/Photo

    Yesterday | Fox News

    Glaucoma is a disease in which there is a buildup of pressure behind the eye. The pressure often damages the optic nerve and can result in vision loss and blindness if not treated properly.

    Comment?

  4. Lymphangiogenic growth factors may be used to cure glaucoma:Finnish studyRead the original story

    Yesterday | Xinhuanet

    Lymphangiogenic growth factors may be used in the future for glaucoma treatment, suggested researchers from University of Helsinki and Wihuri Research Institute of Finland in a latest study published in the Journal of Clinical Investigation.

    Comment?

  5. pSivida Corp Announces Iluvien Receives Marketing...Read the original story

    Tuesday | BioSpace

    ... in the U.S. An investigator-sponsored clinical trial is ongoing for an injectable, bioerodible microinsert to treat glaucoma and ocular hypertension, a product candidate on which Pfizer Inc. has an option. pSivida's FDA-approved RetisertA , licensed ...

    Comment?

  6. pSivida Announces ILUVIENA Receives Marketing Authorization in...Read the original story

    Monday Jul 28 | Business Wire

    ... the U.S. An investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension, a product candidate on which Pfizer Inc. has an option. pSivida's FDA-approved RetisertA , licensed ...

    Comment?

  7. pSivida Announces ILUVIEN Receives Marketing Authorization in Norway...Read the original story

    Monday Jul 28 | Business Wire

    ... the U.S. An investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension, a product candidate on which Pfizer Inc. has an option. pSivida's FDA-approved RetisertA , licensed ...

    Comment?

  8. New glaucoma treatment approvedRead the original story w/Photo

    Monday Jul 28 | Fox News

    Swiss pharmaceutical group Novartis said the European Commission has approved its eyecare unit Alcon's Simbrinza treatment for glaucoma, a chronic, sight-threatening eye disease.

    Comment?

  9. Novartis says Alcon glaucoma treatment approved in EURead the original story w/Photo

    Monday Jul 28 | Reuters

    Swiss pharmaceutical group Novartis said the European Commission has approved its eyecare unit Alcon's Simbrinza treatment for glaucoma, a chronic, sight-threatening eye disease.

    Comment?

  10. The Schlemm's canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel.Read the original story

    Sunday Jul 27 | CiteULike

    In glaucoma, aqueous outflow into the Schlemm's canal is obstructed. Despite striking structural and functional similarities with the lymphatic vascular system, it is unknown whether the SC is a blood or lymphatic vessel.

    Comment?

  11. Europe Factors to Watch-Shares set to bounce; Ryanair eyedRead the original story

    Sunday Jul 27 | Reuters

    ... group Novartis said the European Commission had approved its eyecare unit Alcon's Simbrinza treatment for glaucoma, a chronic, sight-threatening eye disease. TELIASONERA Sources said late on Friday Turkey's Cukurova was expected to pay this week for ...

    Comment?

  12. Swiss stocks - Factors to watch on July 28Read the original story

    Sunday Jul 27 | Reuters

    ... group Novartis said the European Commission had approved its eyecare unit Alcon's Simbrinza treatment for glaucoma, a chronic, sight-threatening eye disease. About 80 of the 106 Swiss banks that signed up for a deal with U.S. tax authorities could ...

    Comment?

  13. Retinal ganglion cell death in glaucoma: the how, the why, and the maybe.Read the original story

    Friday Jul 25 | CiteULike

    Research on the mechanism of cell death in experimental glaucoma indicates that ganglion cells die by apoptosis.

    Comment?

  14. Aerie Pharmaceuticals, Inc. Receives Health Canada "No Objection...Read the original story

    Thursday Jul 24 | BioSpace

    Aerie Pharmaceuticals, Inc. Receives Health Canada "No Objection Letter" To Commence Phase 3 Registration Trial Of Rhopressatm In Patients With Glaucoma In Canada BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.-- --Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and ... (more)

    Comment?

  15. Allergan, Inc. v. Apotex, Inc.Read the original story

    Thursday Jul 24 | JD Supra

    ... prostaglandin analogues (PGF) could alleviate intraocular pressure (IOP), which is associated with the eye disease glaucoma. Bimatoprost is a PGF that received FDA approval in 2001 - and marketed as Lumigan--as an eye drop to treat glaucoma. Hair ...

    Comment?

  16. Aerie Pharmaceuticals, Inc. Receives Health Canada a oeNo Objection...Read the original story

    Thursday Jul 24 | Business Wire

    Aerie Pharmaceuticals, Inc. Receives Health Canada "No Objection Letter" to Commence Phase 3 Registration Trial of Rhopressa TM in Patients with Glaucoma in Canada BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.-- --Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development ... (more)

    Comment?

  17. Implandata Announces Successful Implantation of Micro-Sensor for Intraocular Pressure ...Read the original story

    Thursday Jul 24 | B3C

    ... information at: ) are currently recruiting primary open angle glaucoma patients, undergoing cataract extraction. These patients are eligible to receive the implantable micro sensor for wireless ...

    Comment?

  18. Distinctive developmental origin for a drainage tube in the eyeRead the original story w/Photo

    Tuesday Jul 22 | Science Daily

    Scientists have conducted a comprehensive exploration of an eye structure known as Schlemm's canal: a key gatekeeper for the proper flow of eye fluid, presenting a number of insights relevant to glaucoma and other diseases.

    Comment?

  19. Aerie Pharmaceuticals to Announce Second Quarter 2014 Financial...Read the original story

    Wednesday Jul 23 | Business Wire

    ... clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies. The Company has commenced two Phase 3 registration trials in the United States, named "Rocket 1" and "Rocket 2," ...

    Comment?

  20. Readers Choice 2014 - East Side - Best Place for an Eye ExamRead the original story

    Tuesday Jul 22 | Roseville Review

    ... Services include examinations for eyeglasses and contact lenses, laser vision correction, children's eye disorders, glaucoma treatment and cataract, cornea and plastic surgery. Optical shops are located adjacent to all sites. Clinic physicians are ...

    Comment?